STOCK TITAN
  1. Home
  2. News
  3. PHGE

BiomX Inc - PHGE STOCK NEWS

Welcome to our dedicated news page for BiomX (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on BiomX.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BiomX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BiomX's position in the market.

News
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
Rhea-AI Summary
BiomX Inc. will present data from the Phase 1b/2a study of BX004 for treating cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections at ECCMID 2024. The abstract was ranked as a 'Top Poster', reflecting its high quality and acceptance at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.63%
Tags
conferences clinical trial
-
News
BiomX Announces the Appointment of Susan Blum to its Board of Directors
Rhea-AI Summary
BiomX appoints Susan Blum to its Board of Directors, bringing extensive finance and accounting experience to guide the company's growth. Ms. Blum, currently the CFO of Melinta Therapeutics, , will chair the audit committee, aiding BiomX in integrating Adaptive Phage Therapeutics and advancing clinical programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
management
-
News
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
Rhea-AI Summary
BiomX Inc. (PHGE) announced the receipt of a going concern qualification in its annual report for the fiscal year ended December 31, 2023. This announcement is in compliance with NYSE American regulations and does not alter the previously reported financial statements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.57%
Tags
none
News
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
BiomX Inc. acquires Adaptive Phage Therapeutics, creating a leader in phage therapy with a clinical-stage pipeline. The company closed a $50 million financing to support BX004 and BX211 programs, with key data readouts expected in 2025. Patient recruitment for BX211 Phase 2 trial in Diabetic Foot Osteomyelitis is on track, with topline results expected in Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.85%
Tags
earnings
-
News
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
Rhea-AI Summary
BiomX Inc. (PHGE) to Report Q4 and Full Year 2023 Financial Results and Business Update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.08%
Tags
conferences earnings
-
News
Telum Therapeutics appoints Dr. Subhendu Basu as CEO
Rhea-AI Summary
Telum Therapeutics appoints Dr. Subhendu Basu, an experienced bio pharma leader, as the new CEO. Dr. Basu aims to drive corporate development, expand the pipeline, and advance investigational products into clinical trials. The company's previous CEO, Dr. Díez-Martínez, transitions to COO, highlighting Telum's focus on innovation in engineered phage endolysins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
management
News
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
Rhea-AI Summary
BiomX Inc. completes the acquisition of Adaptive Phage Therapeutics, Inc., creating a leading phage therapy company with two Phase 2 assets targeting chronic pulmonary infections in cystic fibrosis patients and diabetic foot osteomyelitis. A $50 million financing round will support the advancement of these lead product candidates through Phase 2 clinical readouts in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
acquisition
-
News
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
Rhea-AI Summary
BiomX Inc. (PHGE) announces the acquisition of Adaptive Phage Therapeutics, Inc., creating a leading phage therapy company with advanced pipeline assets. The merger agreement includes a private placement financing of $50 million to advance two Phase 2 clinical candidates. The acquisition is expected to close within 30 days, with BiomX stockholders owning 55% and APT stockholders owning 45% of the consolidated entity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
197.66%
Tags
acquisition
-
News
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
Rhea-AI Summary
BiomX Inc. (PHGE) announced that its phage cocktail, BX004, has been granted Orphan Drug Designation by the FDA for the treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis. This follows the Fast Track designation granted in August 2023. CEO Jonathan Solomon expressed optimism about the potential of BX004 to improve the standard of care for CF patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
clinical trial
News
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
Rhea-AI Summary
BiomX Inc. (PHGE) to Host Virtual KOL Event to Discuss Positive Trial Results for BX004 in Cystic Fibrosis Patients with Chronic P. aeruginosa Infections
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
conferences clinical trial
Stock PHGE logo
BiomX Inc

NYSE:PHGE

PHGE Rankings

#5157 Ranked by Market Cap
#3538 Ranked by Stock Gains
N/A Ranked by Dividends

PHGE Stock Data

17.39M
32.39M
29.82%
25.72%
0.4%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
Ness Ziona

About PHGE

biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.